Home・Список акций・TransMedics Group Inc

TransMedics Group Inc

Закрыт

СекторЗдравоохранение

80.5 -1.38

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

78.31

Макс.

81.92

Ключевые показатели
By Trading Economics
Доход	-98M 7.3M
Продажи	13M 174M
P/E Средняя по отрасли	16.998 64.641
Прибыль на акцию	0.3
Рентабельность продаж	4.206
Сотрудники	898
EBITDA	-4.9M 28M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+41.02% upside

Дивиденды
By Acuity
Следующий отчет о доходах	4 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-786M 2.6B
Предыдущая цена открытия	81.88
Предыдущая цена закрытия	80.5

Новостные настроения

By Acuity

65%

35%

289 / 340 Рейтинг в Healthcare

TransMedics Group Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30 июл. 2026 г., 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29 июл. 2026 г., 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28 июл. 2026 г., 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27 июл. 2026 г., 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24 июл. 2026 г., 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22 июл. 2026 г., 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21 июл. 2026 г., 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20 июл. 2026 г., 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Сравнение c конкурентами

Изменение цены

TransMedics Group Inc Прогноз

Целевая цена

By TipRanks

41.02% рост

Прогноз на 12 месяцев

Средняя 115 USD 41.02%

Максимум 175 USD

Минимум 80 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для TransMedics Group Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

10 ratings

Покупка

Удержание

Продажа

Основано на мнении 10 аналитиков, присваивавших рейтинги акциям TransMedics Group Inc – Данные за последние 3 месяца.

Настроения

By Acuity

289 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.